Jason Shafrin, PhD

Healthcare Economist

12/20/2021

Jason Shafrin, PhD

Jason Shafrin, PhD, discusses a paper examining how prices vary for branded, physician-administered drugs which had generic or biosimilar versions introduced before 2005.

Jason Shafrin, PhD, discusses a...

12/20/2021

Journal of Clinical Pathways

Guest Blog

Has Medicine Reached the Digital Age? Five Key Obstacles Digital Technologies Still Need to Overcome

08/26/2021

Jason Shafrin, PhD

David Gruber, MD, MBA

Jason Shafrin, PhD, and David Gruber, MD, MBA, discuss challenges digital health innovators face and what digital health technologies must provide to be successful.

Jason Shafrin, PhD, and David...

08/26/2021

Journal of Clinical Pathways

Healthcare Economist

Which Strategies Are Payers and Employers Using to Cover Ophan Drugs?

06/20/2021

Jason Shafrin, PhD

Jason Shafrin, PhD, discusses a survey which explored affordability challenges posed by orphan drugs from the payer, provider, and employer perspectives.

Jason Shafrin, PhD, discusses a...

06/20/2021

Journal of Clinical Pathways

Healthcare Economist

The Real Cost of Electronic Health Records

06/07/2021

Jason Shafrin, PhD

Jason Shafrin, PhD, discusses the many cost aspects of successfully implementing electronic health records.

Jason Shafrin, PhD, discusses...

06/07/2021

Journal of Clinical Pathways

Healthcare Economist

Impact of COVID-19 on CMS’ Value-Based Programs

06/01/2021

Jason Shafrin, PhD

Jason Shafrin, PhD, discusses the effect quality impacts during COVID-19 will have on Medicare reimbursement to providers through 2024.

Jason Shafrin, PhD, discusses...

06/01/2021

Journal of Clinical Pathways

Pharma Insights

Does COVID-19 Threaten the Progress Pharmaceuticals Have Made in Reducing Cancer Mortality Over the Last 20 Years?

12/16/2020

Joanna P MacEwan, PhD

Jason Shafrin, PhD

Farzad Ali, BPharm, MS

The development and introduction of new pharmaceuticals has played a pivotal role in reducing US cancer deaths. While pharmaceuticals have played a significant role in reducing cancer mortality, winning the war on...

The...

12/16/2020

Journal of Clinical Pathways

Pharma Insights

Open-Source Tools for Value Assessment: A Promising Approach

06/14/2018

Mark T Linthicum, MPP

Jennifer Bright, MPA

Jason Shafrin, PhD

While many advancements have been made thus far in the progression toward value-based health care, there are persistent challenges in the measurement of value. In order to deliver value-based care, health care...

While...

06/14/2018

Journal of Clinical Pathways

Pharma Insights

The Clash: Treatment Advances and Value Measurements in Oncology

04/11/2017

Larry Blandford, PharmD

Jason Shafrin, PhD

Cancer has or will affect nearly every person at some point in their lives, either directly or indirectly. The fight against cancer is central to society; in recent years, treatment advances and prevention strategies...

Cancer...

04/11/2017

Journal of Clinical Pathways